ATAD3A and prostate carcinoma: The high expression of ATAD3A was related to cisplatin resistance in lung adenocarcinoma in our studies, which is in agreement with other studies where silencing ATAd3A expression reduced cisplatin resistance in prostate cancer and cisplatin, doxorubicin, and paclitaxel resistance in uterine cervical cancer[37].